BTK and pulmonary arterial hypertension: For example, cardiotoxicity caused by ALK, ROS1, EGFR-TKIs; aortic coarctation caused by VEGF-TKI; pulmonary hypertension caused by ALK-TKI, interstitial pneumonia caused by EGFR/ALK TKIs, infection caused by BTK inhibitors and other adverse reactions.